INTRODUCTION {#s01}
============

Ischemia/reperfusion (I/R) is a pathological event that occurs in numerous disease states. As the name implies, I/R consists of two significant events, the results of which can cause detrimental cellular damage. Ischemia, the first significant event, refers to the restriction of blood supply to an organ, usually as a result of a blockage within the arterial blood supply by an embolus. Ischemic events are almost always associated with cellular metabolic imbalances and deleterious hypoxia. The second significant event is the reperfusion, or restoration of blood flow and reoxygenation to the affected ischemic area, which can further cause excessive tissue deterioration, initiating destructive inflammatory responses ([@bEltzschig2011]; [@bYellon2007]).

Ischemia/reperfusion injury (IRI) is a significant contributor to the pathology of numerous disease states, particularly post-cardiac trauma. Moreover, IRI can delay the recovery of organ transplantation and can impede patient recovery undergoing treatments. The role of IRI has been investigated in many organs. However, most research has focused on the heart ([@bYellon2007]), brain ([@bHanson2009]), and kidney ([@bFriedmann2014]). The precise molecular mechanism and pathways associated with IRI is not well understood and is heavily debated. As such, the implementation of pharmaceutical strategies has been hampered. Cellular death, however, is a steadfast pathological indicator of IRI. Accordingly, it seems likely that efforts to prevent or arrest the cell death cascade associated with IRI might present as a new and currently unmet therapeutic strategy ([@bEltzschig2011]; [@bGudipaty2018]; [@bLinkermann2013]; [@bSun2018]). Indeed, the investigation and the requirement of a thorough understanding of I/R-related cell death have already been proposed, and likely will be a critical step to develop useful treatment paradigms for IRI ([@bYeo2013]; [@bYu2017]).

Ferroptosis is a recently recognized novel form of cell death and is a potential therapeutic target with an application for many disease states ([@bStockwell2017]). In this review, we intend to discuss the ferroptosis cell death pathway, and how it may negatively impact outcomes of I/R-related cell death in different organs and diseases.

THE CURRENT UNDERSTANDING OF THE PATHOMECHANISM OF ISCHEMIA/REPERFUSION-RELATED CELL DEATH {#s02}
==========================================================================================

The sudden reduction of available tissue oxygen and nutrients is the critical event initiating cellular injury in ischemic tissue. Under ischemic conditions, mitochondria switch from aerobic to anaerobic metabolism, subsequently leading to a reduction in ATP with associated tissue acidification ([@bGores1988]; [@bRaat2009]). The inhibition of ATP generation initiates a rise in intracellular sodium and extracellular potassium levels, thus depolarizing the cell ([@bKimura1986]), and leading to a compensatory transient calcium influx. Concomitantly, calcium-dependent proteolytic enzymes are activated, resulting in apoptosis and necrosis ([@bHalestrap2006]; [@bNayler1981]). Furthermore, during this cellular cascade, other essential ATP-dependent cell functions, such as phosphorylation and enzymatic activity, are also suppressed ([@bGranger2001]), contributing to the cell stress and cell death cascades. Under normal, non-ischemic physiological conditions, several endogenous mechanisms are responsible for reactive oxygen species (ROS) scavenging. However, these mechanisms, and their capacity to effectively scavenge for ROS, is severely negated after I/R ([@bWeisfeldt1988]; [@bZweier1987]). It has been demonstrated that reperfusion of ischemic tissue can lead to a "burst" of ROS, and this oxidative burst can mediate IRI ([@bBecker1987]; [@bHess1984]). The mitochondrial respiratory chain and NADPH oxidases of the NADPH oxidase (NOX) family are believed to be significant sources of ROS ([@bCadenas2018]). Antioxidants, endogenous or exogenous, have been shown to protect from IRI in the liver, kidney, heart, and brain ([@bDare2015]; [@bJiang2015]; [@bNi2019]; [@bZhou2018]). In [Figure 1](#Figure1){ref-type="fig"}, we describe the current knowledge of IRI.

![Changes in the cytoplasmic environment during ischemia](zr-41-3-220-1){#Figure1}

I/R leads to the activation of cell death pathways, where necrosis, apoptosis, and autophagy-associated cell death are suggested to be the key contributors responsible for the pathology of I/R ([@bEltzschig2011]; [@bLinkermann2013]; [@bSun2018]). Furthermore, IRI is punctuated by several cellular events such as the reperfusion associated oxidation burst accompanied by lipid peroxidation ([@bFarmer2013]), and elevated intracellular iron levels ([@bScindia2019]; [@bZhao2018]).

These cellular events, which are consistent with the presentation of iron-dependent non-apoptotic ferroptosis, are preventable by iron chelation and antioxidants. Indeed, Iron chelation has been reported to be beneficial in some animal models of IRI ([@bGalaris2006]; [@bScindia2015]). Furthermore, the observation that iron and ferroptosis mediate cellular damage to organs, and cell death has been frequently documented in recent literature ([@bFriedmann2014]; [@bGao2015]; [@bLinkermann2014]; [@bSkouta2014]; [@bTuo2017]).

REGULATION OF FERROPTOSIS {#s03}
=========================

Ferroptosis is a non-apoptotic form of cell death that is characterized by the accumulation of iron-dependent lipid hydroperoxides to lethal levels ([@bStockwell2017]). Ferroptosis was clearly defined in 2012, when a small chemical screened from a large library, namely erastin, was shown to inhibit antioxidant glutathione synthesis, and subsequently initiate ferroptosis-related cell death, a cell death pathway that could not be rescued by inhibitors of other known cell death forms ([@bDixon2012]). Therefore, ferroptosis was determined to be morphologically, biochemically, and genetically distinct from other forms of cell death, and may also be involved in various diseases ([@bStockwell2017]; [@bWu2018]). In [Figure 2](#Figure2){ref-type="fig"}, we summarize the mechanism and key regulators of ferroptosis from the perspectives of oxidation and antioxidation. Hyperactivity of the oxidation mechanism and weakening of the antioxidant mechanism will both result in ferroptosis via the accumulation of toxic lipid peroxidation.

![The indicated pathways control the sensitivity of ferroptosis](zr-41-3-220-2){#Figure2}

Antioxidant mechanism {#s03.01}
---------------------

Glutathione peroxidase 4 (GPx4) is a selenium-dependent enzyme, which primarily functions as an endogenous antioxidant ([@bCardoso2017]). The catalytic center of GPx4 is a tetrad, comprising of hydrogen bonds between a redox-active cysteine or selenocysteine (Sec), coupled with the nitrogen atoms from the surrounding asparagine (Asn), glutamine (Gln) and tryptophan (Trp) residues. This structure is the key to the extraordinary catalytic efficiency of GPx4, whereby the exposure of surface positive charges account for rapid and selective oxidation of mainly cysteine residues ([@bTosatto2008]). GPx4 has a unique ability as a cytosolic "antioxidant enzyme", whereby it can modulate substrates including H~2~O~2~, small hydroperoxides, hydroperoxides in complex lipids such as phospholipid, cholesterol, and cholesterol ester hydroperoxides, even when inserted into biomembranes or lipoproteins ([@bBrigelius-Flohe2013]; [@bThomas1990]). The chemical properties of GPx4 enable it to act as the central regulator of anti-lipid peroxidation and ferroptosis resistance. Ferroptosis agonists act directly (RSL3) or indirectly (Erastin or Fin56) on GPx4 by attenuating its activity ([@bKe2016]). Glutathione (GSH) and selenium are necessary for the maintenance of GPx4 function and activity ([@bIngold2018]; [@bStockwell2017]).

Erastin and RSL3 were found to trigger RAS mutation-dependent cytotoxicity in 2003 ([@bDolma2003]), and several proteins involved in glutathione metabolism have been implicated in ferroptosis ([@bYagoda2007]). It is now understood that glutamine-induced neuronal death shares the characteristics of ferroptosis ([@bChoi1988]; [@bMurphy1989]), which indirectly highlights the role of glutathione synthesis in the process. GSH is also an important endogenous antioxidant ([@bMeister1983]) and is involved in the regeneration of GPx4 ([@bMaiorino2018]). GSH is synthesized from glutamate, cysteine, and glycine in two-steps, under the catalysis of cytosolic enzymes, glutamate-cysteine ligase (GCL), and glutathione synthetase (GSS) ([@bLiang2019]). Numerous studies indicate that cysteine is essential for cell survival. Human fibroblasts cultured in the cystine-free medium cannot survive without it, and the cystine deprived cell death is caused by glutathione depletion, which in turn can be arrested by the lipophilic antioxidant a-tocopherol ([@bBannai1977]). Cystine is a disulfide formed between two cysteine molecules and is the predominant form of cysteine in the extracellular space ([@bConrad2012]). The exchange of cystine and glutamate across the plasma membrane is facilitated by a cystine/glutamate antiporter system (Xct), which is a disulfide-linked heterodimer composed of two subunits. The first subunit is solute carrier family 3 member 2 (SLC3A2), and the second is the catalytic subunit solute carrier family 7 member 11 (SLC7A11) ([@bLiang2019]). Once cystine is imported into the cell, it is quickly reduced to cysteine. The exchange of cystine/cystathionine with glutamate is the most important event of ferroptosis and is the main target of erastin ([@bDixon2012]). Interestingly, cysteine may be synthesized from methionine by the transsulfuration pathway in certain types of cells ([@bMcBean2012]), and this pathway may be resistant to erastin.

When intracellular selenium is deficient, cysteine replaces selenocysteine in the GPx4 active center ([@bXu2010]). This recombinant Cys mutant GPx4 expressed in *Escherichia coli* exhibits a significant reduction in catalytic efficiency and a 1 000-fold lower activity ([@bYu2014]) when compared with the natural selenoenzyme. However, sodium selenite (Na~2~SeO~3~) supplementation can restore GPx4 activity in methamphetamine-treated SH-SY5Y cells ([@bBarayuga2013]). Selenium is required by GPx4 to prevent ferroptosis from utilizing Sec deprotonation to suppress irreversible hyper-oxidation ([@bIngold2018][@bBrigelius-Flohe2013]). In the central nervous system, Sec is preferred over Cys with its thiol groups, since Sec can deprotonate rapidly under acidic conditions seen in the brain ([@bCardoso2017]; [@bSong2014]).

It was previously believed that ferroptosis was regulated exclusively by GPx4 ([@bYang2014][@bFriedmann2014]). However, inhibition of GPx4 fails to trigger ferroptosis regardless of acyl-CoA synthetase long-chain family member 4 (ACSL4) expression, a pro-ferroptosis gene ([@bDoll2017]). This suggests that alternative resistance mechanisms may exist. Recent evidence indicates that the ferroptosis suppressor protein 1 (FSP1)-coenzyme Q10 (CoQ10)-(nicotinamide adenine dinucleotide phosphate)NAD(P)H pathway co-operates with GPx4 and glutathione to suppress phospholipid peroxidation and ferroptosis, as a stand-alone parallel system ([@bBersuker2019]; [@bDoll2019]). FSP1, previously called apoptosis-inducing factor mitochondrial 2 (AIFM2), was predicted to induce apoptosis by a caspase-1 independent pathway, due to its biochemical similarities to a previously known AIFM1 ([@bWu2002]). Instead of inducing apoptosis, however, FSP1 is recruited to the plasma membrane by myristoylation, where it functions as an oxidoreductase that catalyzes the regeneration coenzyme Q10 (CoQ10) using NAD(P)H ([@bBersuker2019]; [@bDoll2019]). Ubiquinol, the reduced form of CoQ10, is a lipophilic radical-trapping antioxidant (RTA) ([@bFrei1990]), that regulates ferroptosis by halting the propagation of lipid peroxides. Ubiquinol is generated by the mevalonate pathway, which is an essential anabolic pathway using acetyl-CoA ([@bMullen2016]). Small molecules have been shown to initiate ferroptosis by blocking this pathway. For example, FIN56 binds to, and activates, the enzyme squalene synthase, resulting in the depletion of endogenous CoQ10 ([@bShimada2016]).

Oxidation mechanisms {#s03.02}
--------------------

Lipid metabolism plays an indispensable role in physiological and pathological functions in the human body. For example, fatty acids are essential building blocks of cellular membranes and are the mediator of signaling and energy metabolism in cells ([@bOlzmann2019]). Long-chain fatty acids containing two or more double bonds are called polyunsaturated fatty acids (PUFAs), and they are involved in plasma membrane generation and maintenance ([@bGill1997a], [@bGill1997b]). However, the cis double bonds of the methylene groups of PUFAs, are easily oxidized, and the more methylene groups present, the more susceptible the fatty acid is to autoxidation ([@bConrad2019]; [@bRouzer2003]). Ultimately, the accumulation of lipid hydroperoxides is a crucial factor that triggers ferroptosis ([@bDixon2012]; [@bStockwell2017]). Oxidized arachidonic acid (AA)-containing phosphatidylethanolamine (PE) (AA-PE) is a ferroptosis cell death signal. AA is a type of PUFA that can be elongated into adrenoyl (AdA) by elongase ([@bKagan2017]). A recent study indicated that AA-OOH-PE, rather than other types of phospholipids (PL)-OOH, induced ferroptosis ([@bKagan2017]). In this process, the acyl-CoA synthetase long-chain family 4 (ACSL4) catalyzed the formation of AA-CoA ([@bDoll2017]), which esterified into AA-PE by lysophosphatidylcholine acyltransferase 3 (LPCAT3) ([@bDixon2015]). Indeed, AA-PE can be oxidized to AA-OOH-PE by lipoxygenases (LOXs) and reactive oxygen radicals ([@bForcina2019]; [@bYang2016]). Additionally, cytochrome P450 oxidoreductase (POR) facilitates lipid peroxidation via the donation of electrons to downstream effectors in cells undergoing ferroptosis inducing stress ([@bZou2020]). When the level of AA-OOH-PE exceeds the capacity of the reduction system (GPX4 et al.,), ferroptosis occurs ([@bDoll2017]; [@bLagarde2015]; [@bLiang2019]).

Iron is a redox-active metal that can be involved in lipid peroxidation ([@bHassannia2019]), of which there are two contributory pathways. Firstly, iron can be released from the labile iron pool (LIP), subsequently promoting ROS accumulation by the Fenton reaction ([@bKakhlon2002]; [@bKruszewski2003]). Secondly, irons role as an essential reactive element in many enzymes such as lipoxygenases (LOXs), and NADPH oxidases, is directly involved in lipid peroxidation ([@bGrivennikova2006]; [@bHalliwell1994]). These results strongly indicate that proteins associated with iron homeostasis can also regulate ferroptosis. Moreover, the silencing of the iron response element binding protein 2 (IREB2) by sh-RNA has been shown to reduce sensitivity to ferroptosis ([@bDixon2012]). Cysteine desulfurase (NFS1), the iron-sulfur cluster biosynthetic enzyme in eukaryotes, has also been found to inhibit ferroptosis in lung cancer ([@bAlvarez2017]). And prominin2, a ferroptosis stress response protein, increases the resistance to ferroptosis via stimulating iron export ([@bBrown2019]). Autophagy of ferritin in lysosomes can also increase the content of the reduced form of iron ([@bTerman2013]), thus facilitating ferroptosis. Meanwhile, ferritinophagy cargo receptor nuclear receptor coactivator 4 (NCOA4), can mediate the autophagic degradation of ferritin, and its subsequent inhibition is protective to cells from ferroptosis damage ([@bGao2016]; [@bHou2016]). Heme oxygenase-1 (HO-1) can catalyze heme degradation to release ferrous iron, and early research indicates that oxidative stress can induce HO-1 expression via the activation of the p62-Keap1-NRF2 pathway, to antagonize ferroptosis ([@bSun2016]). However, overexpression of HO-1 may accelerate ferroptosis in cancer cells ([@bChang2018]; [@bHassannia2018]).

FERROPTOSIS AS THE MAJOR FORM OF CELL DEATH OCCURRED DURING ISCHEMIA-REPERFUSION {#s04}
================================================================================

In a variety of human conditions, I/R events cause extensive tissue damage, heightened inflammatory responses, and is a major cause of morbidity and mortality. furthermore, there is evidence suggesting that the reduction of IRI may increase organ transplantation success rates ([@bRaat2009]). It is, therefore, important to determine and understand the type of cell death in I/R events, to identify appropriate therapeutic target opportunities. As noted above, recent investigations have provided strong evidence demonstrating how ferroptosis can participate in IRI, and how targeting ferroptosis might be beneficial for I/R conditions.

Brain I/R events {#s04.01}
----------------

According to the data released by the World Health Organization (WHO)([@bWHO2016]), a stroke occurs on average every 5 seconds affecting 15 million people annually, and it is the leading cause of brain injury and subsequent permanent disability. The majority of strokes are caused by the occlusion of a cerebral artery (ischemic stroke) ([@bIadecola2011]). To date, no significant effective therapeutic interventions have been developed to counter the deleterious effects of cerebral I/R ([@bKrishnamurthi2013]; [@bYeo2013]).

The physiological functions of the brain post-stroke result in increased vulnerability to oxidative stress. The brain requires a constant production of high levels of ATP to maintain metabolic activity and neuronal homeostasis ([@bBelanger2011]), and ATP production is impeded in I/R. Additionally, the brain also accumulates more deleterious byproducts of mitochondrial metabolism under ischemic conditions when compared to other organs ([@bCardoso2017]). Further, neuronal membranes are rich in PUFAs, which are easily oxidized ([@bConrad2019]). Accordingly, antioxidant production in the brain is tightly regulated and balanced. Under I/R conditions, iron accumulation in affected brain areas has been observed in both patients, and experimental animal models of cerebral ischemia ([@bDing2011]; [@bPark2011]) ([@bDietrich1988]; [@bFang2013]), and has been proposed as the key mediator of neuronal damage and death ([@bCastellanos2002]; [@bKondo1995], [@bKondo1997]). Consistently, iron chelation therapy has been shown to attenuate the cellular damage observed in the brains of experimental IRI rodent animal models ([@bHanson2009]; [@bPatt1990]).

[@bTuo2017] have recently shown that ischemic stroke can cause pro-ferroptotic iron accumulation via the acute suppression of tau, an Alzheimer's disease protein that can facilitate iron export ([@bLei2012], [@bLei2017]), leading to worsening of IRI-related cellular damage and death ([@bBi2017]). However, IRI-related neuronal damage can be rescued by ferroptosis inhibitors such as liprostatin-1 and ferrostatin-1, strongly suggesting a direct involvement of ferroptosis in brain IRI ([@bTuo2017]). Furthermore, pharmacological supplementation of selenium has been shown to promote the expression of GPx4, which blocks ferroptosis and protects neurons from IRI ([@bAlim2019]). Additionally, the ion channel activating monoterpenoid phenol carvacrol can protect hippocampal neurons against I/R in gerbils by inhibiting GPX4-dependent ferroptosis ([@bGuan2019]). PEBP1 is a scaffold protein inhibitor of protein kinase cascades, and it combines with 15-LOX to promote ferroptosis by the generation of lipid death signals ([@bWenzel2017]). When the PEBP1/15-LOX is upregulated, GPX4 levels and its enzymatic activity is decreased in the cortex following experimentally induced brain injury, further supporting the notion that ferroptosis is involved in IRI pathogenesis of the brain post-injury ([@bWenzel2017]). These findings strongly support the hypothesis that ferroptosis is intricately involved in and likely modulates the extent of brain pathology after IRI.

Heart I/R events {#s04.02}
----------------

Cardiovascular disease is considered the leading cause of morbidity and mortality worldwide among all diseases ([@bStamenkovic2019]). Myocardial reperfusion injury, also known as lethal reperfusion injury, results in the death of cardiac myocytes, which are viable immediately before reperfusion. The destruction of viable cardiac myocytes upon reperfusion ensures that the rate of death or cardiac failure is still high, even with optimally controlled myocardial reperfusion ([@bYellon2007]). Clinical studies indicate that residual myocardial iron is a risk factor for inadequate left ventricular remodeling after reperfusion ([@bBulluck2016]). Notably, evidence indicates that the mitochondria-specific overexpression of GPx4 in mitochondria alleviates cardiac dysfunction following I/R ([@bDabkowski2008]). Inhibition of glutaminolysis, a component of the GSH generation pathway, can also attenuate I/R-associated heart injury by blocking ferroptosis ([@bGao2015]). The cardiac mechanistic target of rapamycin (mTOR) protects the heart against IRI ([@bAoyagi2012]) and was found to exert protective effects against excess iron and ferroptosis ([@bBaba2018]). Ferrostatin-1 and iron chelation can also ameliorate heart failure induced by both acute and chronic I/R ([@bFang2019]), consistent with the notion that targeting ferroptosis can serve as a potential strategy to prevent cardiomyopathy.

Kidney I/R events {#s04.03}
-----------------

Renal IRI, a common cause of acute renal failure, has been widely observed in a variety of clinical events, including renal transplantation, embolic or thrombotic events, and surgical interventions, thus playing a significant role on the morbidity and mortality of patients ([@bPefanis2019]; [@bZhang2014]). Similar to other I/R events summarized above, reperfusion in the kidney generates an increase in reactive oxygen species that can induce cell death ([@bCastaneda2003]; [@bPerico2004]). For some time now, iron has been suggested to play an important role in renal IRI, and iron chelators have been shown to inhibit renal tubular cell death ([@bLinkermann2016]; [@bSogabe1996]).

Due to its specific ability to reduce lipid peroxides, the role of GPx4 in renal IRI has recently been investigated. Knockout of GPx4 induces kidney failure in mice, which presents with molecular features of ferroptosis and can be inhibited by the application of ferroptosis inhibitors ([@bFriedmann2014]). Moreover, subsequent studies have also shown that ferroptosis inhibitors can attenuate renal IRI ([@bFriedmann2014]; [@bLinkermann2014]). The ubiquitous multi-functional protein, augmenter of liver regeneration (ALR), can alleviate IRI, and the silencing of ALR aggravates ferroptosis and is intricately linked to the glutathione--glutathione peroxidase system ([@bHuang2019]). However, the targeting of ferroptosis alone may not be an optimal therapeutic strategy, as two recent studies of renal IRI demonstrate the coexistence of both necrosis and ferroptosis pathways ([@bPefanis2019]), indicating that necrosis and ferroptosis may play a synergistic role in renal IRI ([@bMuller2017]). By using CRISPR/Cas9 technology, [@bMuller2017] found that the pseudokinase mixed lineage kinase domain-like protein (MLKL), a molecular switch to induce necroptotic cell death, drives basal resistance to ferroptosis via the depletion PUFAs, while ACSL4 drives basal resistance to necroptosis rendering the cell membrane less amenable to MLKL-driven membrane permeabilization in renal IRI. These observations suggest that combined therapy should be considered for the treatment of renal IRI. Interestingly, the activin receptor-like kinase (ALK4/5), also known as activin-transforming growth factor (TGF) β receptor, is involved in the stress-induced renal injury, and can suppress cadmium and erastin-induced renal tubular cell death ([@bFujiki2019]), indicating that the renal IRI model may be useful for studying the relationship of ferroptosis and other forms of cell death.

I/R events of other organs {#s04.04}
--------------------------

The role of ferroptosis has been investigated in other organs that can undergo IR events. For example, testicular IRI induces cell death of germ cells and Sertoli cells, and the death of Sertoli cells is explicitly associated with ferroptosis, as indicated by the fact that ferroptosis inhibitors only, and not inhibitors of apoptosis, necrosis or autophagy, protect Sertoli cell from oxygen-glucose deprivation/reoxygenation ([@bLi2018]). Also, ACSL4 was shown to play a critical role in intestinal IRI, which can be protected by ACSL4 inhibition and ferroptosis inhibitors ([@bLi2019]).

CONCLUDING REMARKS {#s05}
==================

Elevated iron and oxidative stress exist in many organs or tissues after I/R, and iron chelating agents have been tested for and indeed demonstrated efficacy in the improvement of outcomes in a variety of symptoms associated with I/R. ([@bDavis1997]; [@bPatt1990]; [@bPrass2002]). However, the use of iron chelators in the clinical setting is hampered by the potential negative impact on blood physiology, and by an inability to target the specific organs requiring therapeutic intervention effectively.

Over the last ten years, clinical trials for iron chelators in IRI have shown limited success ([@bChan2012]; [@bDrossos1995]; [@bLesnefsky1990]). The limitations are likely due to a variety of reasons, including chelating efficiency in iron affected areas, the specific timing of use, heterogeneity among patients, and other adverse off-target side effects, suggesting that by itself iron may not be an optimal target.

A growing number of recent studies link ferroptosis with IRI, and this should not be surprising, given the fact IRI is essentially related to oxidative damage, which is one of the main causes of ferroptosis. These observations should also provide a window for intervention, whereby instead of targeting the initial cause of the disease, it may be possible to target the pathways of cell death initiated by IRI directly. Multiple studies in numerous organs demonstrate that inhibition of ferroptosis, either by chemical inhibitors or genetic ablation of key genes involved in ferroptosis, can protect cells during IRI, strongly suggesting that ferroptosis can serve as a target for drug development. It is therefore imperative that research efforts are undertaken to screen new drug-like compounds for preclinical and clinical tests of ferroptosis inhibitors to treat IRI in the future.
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